Booster shot study aims to keep teens safe from meningitis b

NCT ID NCT06995430

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a booster dose of the meningitis B vaccine (Bexsero) works well and is safe for healthy people aged 10 to 20. It included 312 participants who either got the vaccine as babies or had never received it. The goal was to see if the booster triggers a strong immune response to protect against meningitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningitis meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGITIS

Contacts and locations

Locations

GSK Investigational Site

Espoo, 02230, Finland
GSK Investigational Site

Helsinki, 00100, Finland
GSK Investigational Site

Jarvenpaa, 04400, Finland
GSK Investigational Site

Kokkola, 67100, Finland
GSK Investigational Site

Oulu, 90220, Finland
GSK Investigational Site

Seinäjoki, 60100, Finland
GSK Investigational Site

Tampere, 33100, Finland
GSK Investigational Site

Turku, 20520, Finland
GSK Investigational Site

Florence, 50139, Italy
GSK Investigational Site

Genova, 16132, Italy
GSK Investigational Site

Milan, 20122, Italy
GSK Investigational Site

Novara, 28100, Italy
GSK Investigational Site

Santiago de Compostela, 15701, Spain
GSK Investigational Site

Seville, 41014, Spain
GSK Investigational Site

Bristol, BS2 8BJ, United Kingdom
GSK Investigational Site

London, SW17 0RE, United Kingdom
GSK Investigational Site

Oxford, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.